Accession Number:



Development of Novel Drugs for High-Risk Triple- Negative Breast Cancer Treatment

Personal Author(s):

Corporate Author:

Department of Chemistry and Biochemistry, University of Minnesota Duluth Duluth United States

Report Date:



Triple negative breast cancer TNBC constitutes 1020 of all breast cancers and is associated with aggressive tumor growth, metastasis and poor patient outcome. The standard treatment involves surgery, radiation and chemotherapy. Many of these chemotherapeutics are hampered by their lack of cancer cell selectivity and significant serious side effects. Most patients initially respond to the chemotherapy but a majority relapses and become drug resistant. Hence, novel therapeutics that are selectively toxic to cancer cells are urgently needed. Vigorous glycolysis is the hallmark of all advanced stage tumors. The end products of glycolysis are metabolites such as pyruvate and lactate. These are transported in and out of the cells by monocarboxylate transporters 1 and 4 MCT14 and serve as nutrients for further energy production. We have developed small molecule based MCT14 inhibitors that exhibit an efficient tumor growth inhibition in MCT1 and MCT4 expressing tumor xenograft models. The purpose of this project is to explore the potential of these inhibitors as anticancer agents.

Descriptive Note:

Technical Report,15 Mar 2015,31 Aug 2019



Distribution Statement:

Approved For Public Release;

File Size: